Why Novo missed its sales estimates on weight-loss drug Wegovy: CEO

finance.yahoo.com/news/why-novo-missed-its-sales-estimates-on-weight-loss-drug-wegovy-ceo-164318615.html

In This Article:
Novo Nordisk's (NVO) investors are worried its competition with Eli Lilly (LLY) is heating up and that the first-to-market GLP-1 leader is losing ground.
Even with 72% of the global market share, the competition in the US has been pressuring the company's stock in recent…

This story appeared on finance.yahoo.com, 2025-05-07 16:43:18.
The Entire Business World on a Single Page. Free to Use →